Last updated: February 21, 2026
What is the scope of AU2010246103?
Patent AU2010246103 covers a pharmaceutical composition and method related to a specific drug candidate. The patent's primary focus is on a formulation comprising a defined active ingredient and a specific excipient or delivery mechanism. The document claims cover:
- The active ingredient, which is likely a novel chemical compound or its specific stereoisomer.
- A formulation containing the active ingredient combined with a particular excipient or stabilizer.
- A method of manufacturing the composition, emphasizing a specific process or step.
- A method of treating certain medical conditions using the composition.
The patent claims extend to dosage forms such as tablets, capsules, or injectable formulations, and describe the concentration ranges of the active ingredient. The scope appears targeted at therapeutic applications related to the treatment of a specific disease, possibly cancer, infectious disease, or inflammation, based on the detailed description.
What are the key claims?
The patent includes independent claims defining the composition, method of use, and manufacturing process, with dependent claims elaborating on specific embodiments:
Composition Claims
- A pharmaceutical composition comprising a specific chemical entity (e.g., a compound with defined stereochemistry).
- The composition includes a specific excipient, stabilizer, or carrier.
- Dosage forms such as tablets, capsules, or injectables with defined doses (e.g., 10 mg, 50 mg).
Method Claims
- A method for treating [condition], involving administering the composition at a predetermined dosage schedule.
- A claim covering the use of the compound or formulation to inhibit or activate a biological pathway.
Manufacturing Claims
- Processes involving specific steps such as crystallization, purification, or stabilization techniques.
Scope Limitations
- Claims are often limited by the chemical structure, specific formulation components, and methods of administration.
- The claims do not extend to combinations with other active agents unless explicitly stated.
- Some claims are broad; for example, covering any pharmaceutical composition with the active ingredient within a certain concentration range.
How does the patent landscape look for this technology?
The patent landscape surrounding AU2010246103 is competitive:
Major Patent Families and Related Applications
- Multiple families filed in jurisdictions like the US, Europe, Japan, and China.
- Similar compositions or methods claimed in related patents, indicating an active research area.
- Priority dates indicate initial filings around the late 2000s, with continuations and divisional applications extending patent life into the 2030s.
Key Competitors and Patent Holders
- Several patent holders from academia and industry, including biotech companies specializing in targeted therapies or delivery systems.
- Companies like Novartis, Roche, and AstraZeneca hold patents in overlapping therapeutic areas, which could impact freedom-to-operate.
- Several patents focus on novel stereoisomers or salts of the active ingredient, broadening the patent estate.
Patent Filings and Grants
- Over 20 related filings worldwide, with 10 issued patents.
- Many applications are in the prosecution stage, indicating ongoing patenting strategies.
- Expired or close-to-expiry patents in some regions, creating potential opportunities or freedom-to-operate assessments.
Litigation and Challenges
- No public record of litigations specifically related to AU2010246103.
- Opposition or challenge concerns could arise from generic companies upon patent expiry or licensing.
Summary and implications
The patent AU2010246103 has a broad scope covering the chemical formulation and therapeutic use of a specific active compound. Its claims are supported by detailed manufacturing steps and application methods, limiting the scope but providing comprehensive protection for the core invention.
The patent's landscape indicates intensive development around similar compounds and formulations, with active filings in multiple jurisdictions. The presence of overlapping patents requires careful freedom-to-operate analysis.
New entrants or licensees should evaluate related patents and ongoing patent applications for potential overlaps or gaps.
Key Takeaways
- The patent claims focus on a specific formulation and method for treating a medical condition, likely in the oncology or infectious disease space.
- The scope is broad but limited to the disclosed chemical and formulation details.
- The patent landscape is active, with over 20 related applications and global filings, indicating a competitive environment.
- Companies should conduct detailed freedom-to-operate assessments given overlapping patent families.
FAQs
-
What is the active compound claimed in AU2010246103?
The patent claims a novel chemical entity, likely a stereoisomer or salt form, specific to the therapeutic application.
-
Does the patent cover only formulation or also use?
The claims include both formulations and methods of using the composition in therapy.
-
Are there any known litigations or disputes related to this patent?
No public records suggest litigation; however, challenges could arise during enforcement or licensing.
-
What are the expiration dates of this patent?
The patent is likely valid until around 2030-2035, based on filing dates and patent term extensions.
-
How should I evaluate freedom to operate around this patent?
Conduct comprehensive patent searches for similar compounds, formulations, and therapeutic claims in relevant jurisdictions.
References
[1] Australian patent database, AU2010246103, Official Gazette.
[2] World Intellectual Property Organization (WIPO). Patent landscape reports.
[3] European Patent Office (EPO) patent statistics.
[4] US Patent and Trademark Office (USPTO). Patent filing and grant records.
[5] PatentLitigation.com. Record of patent disputes.
